Valproate pregnancy prevention — GPhC CRA MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: D — Discuss pregnancy prevention requirements and refer to the prescriber urgently
Valproate has major teratogenic and neurodevelopmental risks, and strict pregnancy prevention measures apply. The pharmacist should discuss the need for effective contraception and ensure urgent prescriber or specialist review where requirements are not being met. Abruptly stopping valproate can be dangerous and should not be advised without specialist input. Counselling should be documented sensitively.
Reference: MHRA Drug Safety Update; BNF